Matrixyl — 10mg

Matrixyl is the trade name for Palmitoyl Pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide composed of the pentapeptide sequence Lys-Thr-Thr-Lys-Ser conjugated at the N-terminus to a 16-carbon palmitoyl (palmitic acid) chain. The peptide portion is a direct fragment of the type I procollagen C-propeptide — a region cleaved during collagen maturation — making Matrixyl a synthetic mimic of an endogenous matrikine, a class of peptide signaling molecules released during extracellular matrix turnover that feed back to regulate ECM synthesis. The palmitoyl conjugation increases lipophilicity dramatically, enabling stratum corneum penetration that the bare pentapeptide cannot achieve.

Mechanistically, Matrixyl functions as a matrikine that signals through dermal fibroblast surface receptors (the precise receptor identity remains an active area of research) to upregulate expression of multiple ECM constituents. In vitro studies in cultured human dermal fibroblasts have demonstrated dose-dependent increases in synthesis of type I, III, and IV collagens, fibronectin, hyaluronic acid, and other glycosaminoglycans. Beyond its synthetic-stimulating activity, biophysical studies indicate that the compound modulates a feedback loop in sparse extracellular matrix environments — promoting ECM deposition while simultaneously inhibiting excessive degradation. This dual action distinguishes it pharmacologically from passive collagen-supplementing strategies.

Research applications span dermatological aging studies, wound healing models, ECM biology, and the broader study of matrikine signaling. A landmark 2008 split-face human clinical study published in the British Journal of Dermatology demonstrated that topical Pal-KTTKS at 3 ppm produced statistically significant reductions in wrinkle depth and length compared to placebo over 12 weeks, with effects discernible by both clinical scoring and quantitative image analysis. The compound has been studied at concentrations as low as ~3 ppm in cosmeceutical formulations and at higher concentrations in research-only contexts. Current research lines focus on combinatorial protocols (Matrixyl combined with copper peptides, retinoids, or other ECM-active compounds), penetration optimization, and elucidation of the specific fibroblast receptors mediating its signaling activity.